Ray Dalio's ALNY Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 33.9K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $15.46 M, representing 0.06% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 27.5K shares. Largest reduction occurred in Q3 2021, reducing 3.9K shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +6,099 | New Buy | 6,099 | $169.54 |
| Q3 2021 | -3,865 | Reduce 63.37% | 2,234 | $188.90 |
| Q4 2021 | -2,234 | Sold Out | 2,234 | $0.00 |
| Q2 2022 | +1,512 | New Buy | 1,512 | $146.16 |
| Q3 2022 | -229 | Reduce 15.15% | 1,283 | $200.31 |
| Q4 2022 | -1,283 | Sold Out | 1,283 | $0.00 |
| Q1 2023 | +1,255 | New Buy | 1,255 | $200.32 |
| Q2 2023 | +541 | Add 43.11% | 1,796 | $189.94 |
| Q3 2023 | +90 | Add 5.01% | 1,886 | $177.10 |
| Q4 2023 | +65 | Add 3.45% | 1,951 | $191.41 |
| Q1 2024 | -1,951 | Sold Out | 1,951 | $0.00 |
| Q3 2024 | +2,002 | New Buy | 2,002 | $275.03 |
| Q4 2024 | +4,450 | Add 222.28% | 6,452 | $235.31 |
| Q1 2025 | -6,452 | Sold Out | 6,452 | $0.00 |
| Q3 2025 | +33,911 | New Buy | 33,911 | $456.00 |
Ray Dalio's Alnylam Pharmaceuticals Investment FAQs
Ray Dalio first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q2 2021, acquiring 6,099 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Alnylam Pharmaceuticals, Inc. (ALNY) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q3 2025, adding 33,911 shares worth $15.46 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 33,911 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $15.46 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.06% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 33,911 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.